Latest Acute phase proteins Stories

Dwelling on negative events can increase levels of inflammation in the body, a new Ohio University study finds. Researchers discovered that when study participants were asked to ruminate on a stressful incident, their levels of C-reactive protein, a marker of tissue inflammation, rose. The study is the first time to directly measure this effect in the body. “Much of the past work has looked at this in non-experimental designs. Researchers have asked people to report their tendency to...

Up to 63% Reduction in CRP Response with ISIS-CRP Rx Treatment CARLSBAD, Calif., March 13, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that ISIS-CRP(Rx) selectively reduced severe elevations in C-reactive protein (CRP) in humans. Data from a Phase 1 clinical study showed that ISIS-CRP(Rx) produced statistically significant, dose-dependent reductions in CRP response following an endotoxin challenge, which produces immune responses similar to those...

CARLSBAD, Calif., Feb. 26, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the initiation of a Phase 2 study evaluating ISIS-CRP(Rx) in patients with paroxysmal atrial fibrillation. Atrial fibrillation (AF) involves an irregular and often rapid heart rate that commonly causes poor blood flow to the body. Paroxysmal AF is a type of AF characterized by unpredictable episodes of AF that can occur as frequently as every day. Patients with AF can experience chest...

Elevated levels of C-reactive protein, a marker of inflammatory disease, appear to be associated with increased risk of psychological distress and depression in the general population of adults in Denmark, according to a report published Online First by Archives of General Psychiatry, a JAMA Network publication. Depression is one of the leading causes of disability and previous studies suggest that low-grade systemic inflammation may contribute to the development of depression. C-reactive...

SOMERVILLE, N.J., Dec. 7, 2012 /PRNewswire/ -- Ethicon Biosurgery, Division of Ethicon, Inc., a worldwide leader in hemostasis and sealing solutions, announced today that the U.S. Food and Drug Administration (FDA) has approved EVARREST(TM) Fibrin Sealant Patch, a novel product that rapidly and reliably aids in stopping problematic bleeding during surgery. Unexpected and uncontrollable bleeding during surgery poses a significant challenge to surgeons, and in some surgical...

New insights into what causes uncontrollable bleeding in hemophilia patients are provided in a study published by Cell Press on November 20th in the Biophysical Journal. By revealing that blood clots spread in traveling waves through vessels, the study offers new strategies that could lead to the development of more effective treatments for hemophilia as well as common cardiovascular disorders. "Disorders of blood coagulation are a leading and immediate cause of mortality and morbidity in...

BEIJING, March 23, 2012 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), one of the leading plasma-based biopharmaceutical companies in the People's Republic of China, today announced that its indirectly owned subsidiary, Shandong Taibang Biological Products Co., Ltd. ("Taibang"), recently received approval from the China State Food and Drug Administration ("SFDA") to begin clinical trials for its human fibrinogen to be...

ANNAPOLIS, Md., Sept. 1, 2011 /PRNewswire/ -- This month, Californians are recognizing "Plasma Protein Therapies Month," by raising awareness for the valuable contributions of plasma donors throughout the "Golden State" and for the rare, genetic diseases treated with the therapies that are made possible through plasma donation. Plasma protein therapies, which include plasma-derived therapies and recombinant blood clotting factors (a biotechnology product), are used every day to treat people...

ANNAPOLIS, Md., Sept. 1, 2011 /PRNewswire/ -- This month, Florida and California are recognizing "Plasma Protein Therapies Month," by raising awareness for the valuable contributions of plasma donors and for the rare, genetic diseases treated with the therapies that are made possible through plasma donation. Plasma protein therapies, which include plasma-derived therapies and recombinant blood clotting factors (a biotechnology product), are used every day to treat people with bleeding...

KING OF PRUSSIA, Pa., Feb. 18, 2011 /PRNewswire/ -- CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Corifact(TM), Factor XIII Concentrate (Human), for the routine prophylactic treatment of congenital factor XIII (FXIII) deficiency. Corifact, already available for use in 12 countries throughout the world under the trade name Fibrogammin®- P, is the first and only FXIII concentrate approved in the U.S. Congenital FXIII...